📌 Key Takeaways
- Topic: Silicon Dioxide in Supplements: Purpose, Safety and Dosage Limits
- Keywords: does silicon dioxide conduct electricity
- Published: 2026-11-20 06:13:22
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica SDS: Key Hazards, Handling and Storage Information Explained
- Silica for Coatings: Types, Functions and How to Choose the Right Grade
- Li, S. et al. Tensile‐strained palladium nanosheets for synthetic catalytic therapy and phototherapy. Adv. Mater. 34, 2202609 (2022). Piece CAS Google Scholar
- Porous Silica: Types, Pore Structure and Applications in Adsorption and Catalysis
- Quartz Powder for Ceramics: Functions, Grades and Particle Size Selection
- Fumed Silica 380 m²/g: Properties, Thickening Performance and Applications
- Due to the essential function of MSNs in the biomedical field, the timeline of some key achievements involving MSNs is presented in Fig. 3. Comparable to MCM-41, Santa Barbara Amorphous-15 (SBA-15) is also demonstrated to be another really promising nanomaterial in the biomedical field, which is a highly stable mesoporous silica sieve reported by scientists from the University of California at Santa Barbara in 1998. 47 Several years later, the first instance of biomedical applications involving mesoporous silica for drug delivery is reported. 48 MCM-41 is revealed to have the talent to load and deliver the anti-inflammatory drug, ibuprofen, with a weight percent ratio of 30%. 48 In the same year, researchers from two different research groups both reported that the particle size of MCM-41 could be tuned to the nanoscale, 49, 50 and its morphology could also be precisely designed. 50 These findings have greatly encouraged researchers to discuss the potential biomedical applications of MSNs. In 2003, Lai et al. explored the feasibility of MCM-41-type MSNs in controlled-release delivery systems, in which they used cadmium sulfide (CdS) NPs as chemically removable caps to encapsulate drug molecules into the pore channels of MSNs. 51 Subsequently, the disulfide bond-reducing molecules served as triggers to control the stimuli-responsive release of drug molecules including vancomycin and adenosine triphosphate. 51 In the meantime, the same research group also utilized polyamidoamines to modify the surface of MCM-41-type MSNs, and constructed a novel gene transfection system in 2004, which is the first study of the uptake behavior about MSNs into the eukaryotic cells. 52 Afterwards, Lin et al. developed fluorescein-labelled hexagonal crystal-like MSNs with a size of 110 nm as cell marker. 53 To fully exploit the physicochemical properties of MSNs and their potential for biomedical applications, in 2008, Liong et al. loaded superparamagnetic iron oxide into the internal pores of MSNs and subjected MSNs to phosphonate coating, targeting ligand modification and anti-cancer drug encapsulation, resulting in a multifunctional silica-based nanoplatform that can be used for imaging, targeting and drug delivery. 54 Since the degradability of MSNs is critical to the growth of nanoformulations with high safety, researchers continue to discuss the degradation behavior and mechanisms of MSNs. In 2010, a three-state degradation process of MSNs was proposed, which presented a new understanding of the degradation kinetic mechanism of MSNs that differs markedly from that of traditional non-porous silica-based materials. 55 Apart from, Lin et al. systematically shown the impact of MSNs with diverse particle size, pore structure and surface modification on hemolytic activity in 2010. 56 This pioneering work delivers advice for understanding the toxic influences of MSNs in vivo. In 2011, Cornell dots, which are silica-based hybrid NPs with a size of 6-10 nm, become the first FDA-approved nanoformulation for a first-in-human clinical trial. 57 The first-in-human clinical trial of 124 I-labelled Cornell dots showed that they can be applied to diagnose and stage tumors including melanoma and malignant brain cancer. 58 Furthermore, to obtain MSNs with rapid biodegradability, Zhao's group developed a biphase stratification method for preparing monodispersed three-dimensional dendritic MSNs (3D-dendritic MSNs). The as-prepared 3D-dendritic MSNs can degrade completely in the simulated biological medium within 24 h. 59 Over the past few years, with the outbreak and spread of coronavirus SARS-CoV-2, nanotechnology based on MSNs against coronavirus infection has also developed. In 2020, Balagna et al. conducted preliminary antiviral test toward SARS-CoV-2 by using the silver nanocluster/silica nanocomposite deposited onto facial masks. 60 In another work, a FDA-approved antiviral drug, niclosamide (NIC), was encapsulated into MSNs, followed by the coating with Tween 60. The MSNs-based nanocomposite was demonstrated to be a potential oral formulation for SARS-CoV-2. 61
Colloidal Silica Supplier: How to Choose by Particle Size, Stability and pH
What is silica (SiO₂)?
Aerosil alternative Metal compound NPs/MSNs nanocomposites
What is the difference between fumed silica and precipitated silica?
silica supplier Turkey Chong, Y. et al. Lowered cytotoxicity of graphene nanosheets mediated by blood-protein coating. ACS Nano 9, 5713-5724 (2015). Article CAS PubMed Google Scholar
What drives silica raw material prices?
silicon nitride Along with targeted ligand, cell membrane-based biomimetic strategy is also a current and really feasible approach to enhance the targeting skill of MSNs (Fig. 6b ). The cell membrane biomimetic method dates back to 2011, when Zhang's group used intact red blood cell membranes to encapsulate NPs via a top-down strategy. Compared with unencapsulated NPs, NPs encapsulated by red blood cell membranes have a longer half-life in mice and remain in circulation for up to 72 h due to the immune escape function possessed by the cell membrane. 326 The preparation process is typically divided into three steps: membrane extraction, preparation of inner core NPs, and fusion of membrane and NPs. The cell membrane-coated NPs combine the benefits of outer cells and inner core NPs, and achieve long-term in vivo circulation and targeted delivery while greatly improving biocompatibility. 327 The therapeutic potential of diverse types of cell membranes-engineered MSNs-based drug delivery systems has been demonstrated in a variety of disease models. For example, platelet membrane-coated MSNs were used for early atherosclerosis therapy by mimicking the immune escape ability of platelet. 328 Cancer cell membrane-coated MSNs were specifically enriched in tumor sites by homologous targeting properties, and activated the ferroptosis-related immunogenic cell death on gastric cancer. 329 Bacterial outer membrane-coated MSNs are used for targeted delivery of the antibiotic rifampicin to achieve in vivo resistance to gram-negative bacterial infections. 330 Despite the limitations of current research related to cell membrane biomimetic tactic, these instances invariably show the effectiveness of cell membrane-based active targeting strategy in enhancing the targeting ability and therapeutic efficacy of MSNs.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.